Antibody Therapeutics in Early Clinical Development: Format, Target, and Disease Trends
Janice M. Reichert, PhD, Chief Operating Officer, The Antibody Society
Targeting ROR1 with Antibody-Based Cancer Therapy
Christoph Rader, PhD, Professor, Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida
Trastuzumab Deruxtecan – Successful ADC Development from Payload Selection to Multi-Indication Approval
Gerold Meinhardt, MD, PhD, Vice President – Asset & Portfolio Management, Global Team Lead, DS-8201/ENHERTU, Daiichi Sankyo, Inc.
Mirvetuximab Soravtansine: A Novel FR Alpha-Targeted ADC for Platinum-Resistant Ovarian Cancer
Elisabeth Diver, MD, Medical Director, ImmunoGen